GCM
RXRX icon

Graham Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Graham Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Buy
39,650
+27,393
+223% +$91.2K ﹤0.01% 1096
2026
Q1 		$37.6K Buy
+12,257
New +$47.4K ﹤0.01% 1101
2022
Q4 		– Sell
-123,702
Closed -$1.32M – 1306
2022
Q3 		$1.32M Buy
123,702
+80,505
+186% +$815K 0.05% 365
2022
Q2 		$351K Buy
+43,197
New +$289K 0.01% 773

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Graham Capital Management's RXRX Position: Q2 2026 in Review

Graham Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 223% in Q2 2026, buying an estimated $91.2K and bringing the position to 39,650 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Graham Capital Management first reported a position in RXRX in Q2 2022 and has held it in 4 quarters since. The position peaked at $1.32M in Q3 2022. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Graham Capital Management held 39,650 shares of Recursion Pharmaceuticals worth $146K as of Q2 2026.
  • Graham Capital Management bought 27,393 Recursion Pharmaceuticals shares in Q2 2026, an estimated $91.2K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1096 holding.
  • Graham Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
  • Graham Capital Management's Recursion Pharmaceuticals position peaked at $1.32M in Q3 2022.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.